Clinical Trials

MainTitle

Safety and Pharmacokinetic Study of Tenofovir Alafenamide (TAF)/Elvitegravir (EVC) Administered Rectally

This study is currently recruiting participants. (see Contacts and Locations)

Verified June 2020 by National Institute of Allergy and Infectious Diseases (NIAID)

Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)

Collaborator
CONRAD

Information provided by (Responsible Party)
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier
NCT04047420

First received: August 5, 2019
Last updated: June 5, 2020
Last Verified: June 2020
History of Changes
Purpose

Purpose

The purpose of this study is to evaluate the safety and pharmacokinetics of rectal administration of a tenofovir alafenamide (TAF)/elvitegravir (EVG) insert at two dose levels in HIV-uninfected individuals.

Condition Intervention Phase
HIV Infections

Drug : TAF/EVG Insert
Phase 1

Study Type: Interventional
Study Design: Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Phase 1 Open Label Safety and Pharmacokinetic Study of Rectal Administration of a Tenofovir Alafenamide/Elvitegravir Insert at Two Dose Levels

Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Primary Outcome Measures

  • Frequency of all Grade 2 and higher adverse events (AEs) [ Time Frame: Measured through Month 11 ]
    Graded per the Division of AIDS (DAIDS) Table for Grading Adult and Pediatric Adverse Events, Corrected Version 2.1, July 2017 and/or Addenda 1, 2 and 3 (Female Genital [Dated November 2007], Male Genital [Dated November 2007] and Rectal [Clarification Dated May 2012] Grading Tables for Use in Microbicide Studies).
  • EVG concentrations in blood [ Time Frame: Measured through Week 13 ]
    Based on laboratory evaluations
  • EVG concentrations in rectal fluid [ Time Frame: Measured through Week 13 ]
    Based on laboratory evaluations
  • EVG concentrations in rectal mucosal tissue homogenates [ Time Frame: Measured through Week 13 ]
    Based on laboratory evaluations
  • TAF concentrations in blood [ Time Frame: Measured through Week 13 ]
    Based on laboratory evaluations
  • TAF concentrations in rectal fluid [ Time Frame: Measured through Week 13 ]
    Based on laboratory evaluations
  • TFV concentrations in blood [ Time Frame: Measured through Week 13 ]
    Based on laboratory evaluations
  • TFV concentrations in rectal fluid [ Time Frame: Measured through Week 13 ]
    Based on laboratory evaluations
  • TFV-DP concentration in rectal mucosal tissue homogenates [ Time Frame: Measured through Week 13 ]
    Based on laboratory evaluations
  • TFV-DP concentration in rectal mucosal tissue cell isolates [ Time Frame: Measured through Week 13 ]
    Based on laboratory evaluations
Secondary Outcome Measures:
  • Percentage of participants who report of overall acceptability of the TAF/EVG Insert applied rectally [ Time Frame: Measured through Week 13 ]
    Based on participant report

Estimated Enrollment: 20
Study Start Date: December 11, 2019
Estimated Study Completion Date: August 31, 2020
Estimated Primary Completion Date: August 31, 2020 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Experimental: Tenofovir Alafenamide (TAF)/Elvitegravir (EVG) Insert
On the first dosing visit (Visit 3), participants will receive a single TAF/EVG Insert for rectal administration. On the second dosing visit (Visit 7), after a washout period of at least 7 days, participants will receive two TAF/EVG Inserts for rectal administration. Each participant will be on study for approximately 6-13 weeks.
Drug: TAF/EVG Insert

TAF/EVG Insert (20/16 mg) administered rectally by study staff

Detailed Description:

This study will evaluate the safety and pharmacokinetics of rectal administration of a tenofovir alafenamide (TAF)/elvitegravir (EVG) insert at two dose levels in HIV-uninfected individuals.
All participants will receive a single TAF/EVG Insert at Study Visit 3. After a washout period of at least 7 days, participants will receive two TAF/EVG Inserts at Study Visit 7. The inserts will be administered rectally by study staff. After each dosing visit, samples will be collected over a 3-day period.
Participants will attend 10 study visits and will be followed for approximately 6 to 13 weeks. Study visits may include physical and rectal examinations; collection of blood, urine, rectal and vaginal fluid; and interviews. The total duration of the study will be approximately 11 months.

Eligibility

Eligibility

Ages Eligible for Study: 18 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: Yes  

Criteria

Inclusion Criteria:

  • Individuals who are 18 years of age or older at Screening, verified per site standard operating procedure (SOP)
  • Able and willing to provide written informed consent to be screened for and enrolled in MTN-039
  • HIV-1/2 uninfected at Screening and Enrollment, per applicable algorithm in the study protocol and willing to receive HIV test results
  • Able and willing to provide adequate locator information, as defined in site SOP
  • Able to communicate in spoken and written English
  • Available for all visits and able and willing to comply with all study procedural requirements
  • In general good health at Screening and Enrollment, as determined by the site Investigator of Record (IoR) or designee
  • At Screening, history of consensual receptive anal intercourse (RAI) at least once in lifetime per participant report
  • Willing not to take part in other research studies involving drugs, medical devices, genital or rectal products, or vaccines for the duration of study participation (including the time between Screening and Enrollment)
  • Willing to comply with abstinence and other protocol requirements as outlined in the study protocol
  • For participants of childbearing potential: a negative pregnancy test at Screening and Enrollment
  • For participants of childbearing potential: Per participant report at Enrollment, using an effective method of contraception for at least 30 days (inclusive) prior to Enrollment and intending to use an effective method for the duration of study participation. Effective methods include:
    • Hormonal methods
    • Intrauterine device (IUD) inserted at least 30 days prior to Enrollment (but not past the maximum length of recommended usage according to package instructions)
    • Sterilization (of participant or partner, as defined in site SOPs)
    • Sexually abstinent as defined by abstaining from penile-vaginal intercourse for 90 days prior to Enrollment and intending to remain abstinent for the duration of study participation; this includes having sex exclusively with individuals assigned female sex at birth


    Exclusion Criteria:
  • At Screening:
    • Hemoglobin Grade 1 or higher*
    • Platelet count Grade 1 or higher*
    • Aspartate aminotransferase (AST) or alanine transaminase (ALT) Grade 1 or higher*
    • Serum creatinine greater than 1.3 times the site laboratory upper limit of normal (ULN)
    • International normalized ratio (INR) greater than 1.5 times the site laboratory ULN
    • History of inflammatory bowel disease by participant report
    • Positive hepatitis B surface antigen (HBsAg) test result
    • *As per the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events Corrected Version 2.1, July 2017.
    • Note: Otherwise eligible participants with an exclusionary test result (other than HIV) can be re-tested during the screening process. If a participant is re-tested and a non-exclusionary result is documented within 45 days of providing informed consent for screening, the participant may be enrolled.
  • Anticipated use of and/or unwillingness to abstain from the following medications during study participation:
    • Anticoagulant medications
    • Non-study rectally-administered medications and any products containing nonoxynol-9 (N-9)
  • Known adverse reaction to any of the components of the study product
  • Use of approved or other investigational pre-exposure prophylaxis (PrEP) for HIV prevention within 3 months prior to Enrollment, and/or anticipated use and/or unwillingness to abstain from PrEP during trial participation
  • Use of post-exposure prophylaxis (PEP) for potential HIV exposure within 6 months prior to Enrollment
  • Condomless RAI and/or penile-vaginal intercourse with a partner who is known to be HIV-positive or whose status is unknown in the 6 months prior to Enrollment
  • History of transactional sex in the 12 months prior to Enrollment
  • Non-therapeutic injection drug use or use of non-therapeutic, non-injection stimulant drugs in the 12 months prior to Enrollment
  • Participation in research studies involving drugs, medical devices, genital or rectal products, or vaccines within 30 days of the Enrollment Visit
  • Per participant report, medical records, clinical diagnosis and/or diagnostic testing at either Screening or Enrollment:
    • Diagnosis or treatment of an anogenital sexually transmitted infection (STI) in the 3 months prior to enrollment (including window between Screening and Enrollment).
    • Symptoms, clinical or laboratory diagnosis of active pharyngeal, anorectal, or reproductive tract infection (RTI) requiring treatment per current Centers for Disease Control and Prevention (CDC) guidelines (http://www.cdc.gov/std/treatment).
    • Current symptomatic urinary tract infection (UTI).
      • Infections requiring treatment include Neisseria gonorrhea (GC), Chlamydia trachomatis (CT) infection, syphilis, active herpes simplex virus (HSV) lesions, or symptomatic genital warts, chancroid, pelvic inflammatory disease (PID), bacterial vaginosis (BV), symptomatic vaginal candidiasis, and trichomoniasis.
      • Note: Otherwise eligible participants with an exclusionary UTI, BV and/or candida finding may be re-tested during the screening process.
  • For participants of childbearing potential: Pregnant or breastfeeding at either Screening or Enrollment or planning to become pregnant during study participation
    • Note: A documented negative pregnancy test performed by study staff is required for inclusion; however, a self-reported pregnancy is adequate for exclusion from screening/enrollment into the study.
  • For participants of childbearing potential: Last pregnancy outcome 90 days or less prior to Screening
  • Has any other condition that, in the opinion of the IoR/designee, would preclude
informed consent, make study participation unsafe, complicate the interpretation of study outcome data, or otherwise interfere with achieving the study objectives including any significant uncontrolled active or chronic medical condition.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT04047420

Locations

United States, Alabama
Alabama CRS Recruiting
Birmingham, Alabama, United States, 35294
Contact: Faye Heard, M.P.H.    205-996-4405    fhoward@uabmc.edu
United States, Pennsylvania
University of Pittsburgh CRS Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Dawn R. Weinman    412-383-1748    drw38@pitt.edu

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)
CONRAD

Investigators

Study Chair: Sharon A. Riddler, MD, MPH University of Pittsburgh
More Information

More Information


Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)  
ClinicalTrials.gov Identifier: NCT04047420   History of Changes  
Other Study ID Numbers: MTN-039  
  38470  
Study First Received: August 5, 2019  
Last Updated: June 5, 2020  
Individual Participant Data    
Plan to Share IPD: Undecided  

Studies a U.S. FDA-regulated Drug Product: Yes  
Studies a U.S. FDA-regulated Device Product: No  

Additional relevant MeSH terms:
HIV Infections

ClinicalTrials.gov processed this data on August 07, 2020
This information is provided by ClinicalTrials.gov.